AstraZeneca and Cleveland Clinic Abu Dhabi team up for $50 million clinical trials action plan
Global biopharmaceutical company AstraZeneca is to invest $50 million to carry out dozens of clinical trials in Abu Dhabi in a major partnership with one of the emirate's leading hospitals. The company is joining forces with Cleveland Clinic Abu Dhabi in a long-term drive to address pressing healthcare challenges, with the first studies expected to start before the end of the year. About 30…
AstraZeneca, a global biopharmaceutical company, has announced a $50 million investment to conduct numerous clinical trials in Abu Dhabi through a partnership with Cleveland Clinic Abu Dhabi. The collaboration aims to address pressing healthcare challenges, with the first studies scheduled to commence by the end of the year. The initiative will focus on advancing treatments for cardiovascular, renal, and metabolic diseases, which contribute significantly to mortality in the UAE.
Iskra Reic, AstraZeneca's international executive vice president, revealed that six studies have already been finalized, and the first is set to begin soon. The partnership with Cleveland Clinic Abu Dhabi will expand the collection of local healthcare data and enable more patients from the region to participate in global clinical trials.
AstraZeneca has also formed a global collaboration with Oracle, focusing on hypertension care and clinical research in Abu Dhabi using AI and real-world data. Both partnerships prioritize patient outcomes, healthcare system sustainability, and the integration of AI in disease detection and treatment.
Written by urgent.news from The National UAE's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
